Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoMed TherapeuticsFRA:F98 -9.58%19 Gross Margin % is 70.54% as of Dec. 2025, which is 8% below its 10-year median of 76.94. GuruFocus rates FRA:F98 with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 733 Biotechnology companies, CytoMed Therapeutics ranks better than 71.08% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
CytoMed Therapeutics had a gross margin of 70.54% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
CytoMed Therapeutics Gross Margin % Related Terms
CytoMed Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for CytoMed Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:F98 vs LEXX, INAB, TRAW: Gross Margin % Comparison
For the Biotechnology subindustry, CytoMed Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoMed Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where CytoMed Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
CytoMed Therapeutics (FRA:F98) has a Gross Margin % of 70.54% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on CytoMed Therapeutics and its competitors. This is near median its historical median of 76.94. Over the past decade, CytoMed Therapeutics' Gross Margin % has ranged from 75.00 to 78.88. According to the industry distribution chart, CytoMed Therapeutics ranks #212 out of 733 companies in the Biotechnology industry, placing it in the top 28.9%.
Is CytoMed Therapeutics' Gross Margin % too high?
CytoMed Therapeutics' current Gross Margin % of 70.54% is near median its 10-year median of 76.94. Over the past 10 years, this metric has ranged from a low of 75.00 to a high of 78.88. The Biotechnology industry median Gross Margin % is 60.90. CytoMed Therapeutics' value of 70.54% is 15.8% above this industry median. Based on the distribution chart, CytoMed Therapeutics ranks #212 out of 733 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CytoMed Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' Gross Margin % compare to LEXX and INAB?
According to the Biotechnology industry distribution chart, CytoMed Therapeutics ranks #212 out of 733 companies for Gross Margin %. This puts CytoMed Therapeutics in the upper half of its industry. The industry median Gross Margin % is 60.90. CytoMed Therapeutics' value of 70.54% is 15.8% above this benchmark. Historically, CytoMed Therapeutics' own Gross Margin % has ranged from 75.00 to 78.88 over the past decade. While the company's 10-year median is 76.94 vs. the industry median of 60.90, CytoMed Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytoMed Therapeutics's current Gross Margin % of 70.54% is 15.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on CytoMed Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoMed Therapeutics's current Gross Margin % is 70.54%, which is near median its own 10-year median of 76.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (FRA:F98) has a current Gross Margin % of 70.54%. The current Gross Margin % is 70.54%, which is near median its 10-year median of 76.94 and 15.8% above the Biotechnology industry median of 60.90. CytoMed Therapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For CytoMed Therapeutics (FRA:F98), the current Gross Margin % is 70.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
19GF Score
Get the complete analysis for FRA:F98
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F98 has been successfully added to your 
